igf2bp1 Antibody

What is IGF2BP1 and why is it significant in research?

IGF2BP1 is an oncofetal RNA binding protein that belongs to the IGF2BP family, which consists of three highly related (~80% similarity) paralogues containing six RNA binding domains. It regulates the stability, localization, translation, and alternative splicing of target mRNAs . IGF2BP1 is particularly significant in research because it is expressed during embryonic development, downregulated after birth, but reactivated in numerous cancer types where it associates with poor prognosis and reduced survival . Its ability to synergize with mutations in KRAS to enhance signaling and oncogenic activity makes it a valuable research target for potential cancer therapeutics .

What are the common applications for IGF2BP1 antibodies in laboratory research?

IGF2BP1 antibodies are versatile research tools with multiple validated applications:

These applications have been documented in numerous publications, making IGF2BP1 antibodies valuable tools for investigating RNA-protein interactions, cellular localization, and expression patterns .

How can researchers verify the specificity of an IGF2BP1 antibody?

Verification of IGF2BP1 antibody specificity requires a multi-faceted approach:

• Western blot analysis: IGF2BP1 should be detected at the expected molecular weight (calculated at 63 kDa but typically observed at 65-70 kDa) . Known IGF2BP1-expressing cell lines like HEK-293, Jurkat, A375, HepG2, and HuH-7 should show positive signals .

• Knockout/knockdown controls: Compare antibody reactivity between wild-type samples and those with IGF2BP1 knockout or knockdown. Valid antibodies should show reduced or absent signal in the knockout/knockdown samples .

• Cross-reactivity assessment: Test the antibody against other IGF2BP family members (IGF2BP2, IGF2BP3) to ensure it specifically recognizes IGF2BP1.

• Immunoprecipitation validation: Perform IP followed by mass spectrometry or Western blot to confirm the antibody captures the intended target.

Which cell lines are recommended as positive controls for IGF2BP1 antibody validation?

Based on validated data, researchers should consider the following cell lines as positive controls for IGF2BP1 antibody testing:

Additionally, mouse and rat kidney tissues have demonstrated positive reactivity with IGF2BP1 antibodies, making them useful for cross-species validation studies .

How does IGF2BP1 regulate β-actin mRNA and what methodologies can assess this interaction?

IGF2BP1 plays a crucial role in regulating β-actin mRNA fate through multiple mechanisms:

• Transport regulation: IGF2BP1 facilitates the transport of β-actin mRNA to specific cellular locations, particularly in neurons. Studies using IGF2BP1 knockout models have demonstrated significantly decreased β-actin mRNA transport at steady state .

• Anchoring function: IGF2BP1 is essential for anchoring β-actin mRNA at specific subcellular sites. In the absence of IGF2BP1, the anchoring of endogenous β-actin transcripts is notably impaired .

• Translational control: IGF2BP1 regulates the translation of β-actin mRNA. IGF2BP1-deficient neurons exhibit increased β-actin protein content, suggesting a role in translational repression .

Methodologies to assess these interactions include:

• RNA Immunoprecipitation (RIP) to confirm binding between IGF2BP1 and β-actin mRNA

• Single-molecule fluorescence in situ hybridization (smFISH) to visualize β-actin mRNA distribution

• Live-cell imaging using endogenously labeled β-actin mRNA (e.g., MS2-GFP system) to track transport dynamics

• Immunofluorescence to quantify β-actin protein levels in the presence/absence of IGF2BP1

What experimental approaches can be used to investigate IGF2BP1's role in cancer progression?

Investigating IGF2BP1's oncogenic functions requires sophisticated experimental designs:

• Expression correlation studies: Analyze IGF2BP1 expression levels across cancer tissues and correlate with patient outcomes, tumor stage, and metastatic potential.

• Target RNA identification: Employ CLIP-seq (Cross-linking immunoprecipitation followed by high-throughput sequencing) using validated IGF2BP1 antibodies to comprehensively identify cancer-relevant RNA targets.

• Functional knockdown/knockout studies: Generate stable IGF2BP1 knockdown or knockout cancer cell lines to assess effects on:

  • Proliferation and colony formation

  • Migration and invasion capabilities

  • Resistance to chemotherapeutic agents

  • In vivo tumor growth and metastasis using xenograft models

• Small molecule inhibitor screening: Test compounds that inhibit the interaction between IGF2BP1 and its RNA targets, particularly focusing on the hydrophobic surface at the boundary of KH3 and KH4 domains that has been identified as critical for binding to KRAS RNA .

• Signaling pathway analysis: Investigate how IGF2BP1 modulates oncogenic signaling cascades, particularly in KRAS-mutated cancers, using phospho-specific antibodies to detect pathway activation .

How can researchers effectively design experiments to study IGF2BP1-mediated post-transcriptional regulation?

Designing rigorous experiments to study IGF2BP1-mediated post-transcriptional regulation requires careful consideration of multiple factors:

• RNA binding site identification:

  • Perform CLIP-seq or similar techniques using validated IGF2BP1 antibodies

  • Identify consensus binding motifs through bioinformatic analysis

  • Validate binding using mutagenesis of predicted binding sites

• RNA stability assessment:

  • Measure half-life of target RNAs in IGF2BP1-expressing versus knockout/knockdown cells

  • Use actinomycin D chase experiments to block transcription and isolate stability effects

  • Perform polysome profiling to assess translation efficiency

• Subcellular localization studies:

  • Use fractionation combined with RT-qPCR to quantify target RNA distribution

  • Perform dual immunofluorescence/FISH to visualize co-localization of IGF2BP1 and target RNAs

  • Employ live-cell imaging with fluorescently tagged components

• Functional domain analysis:

  • Generate IGF2BP1 constructs with mutations in specific RNA-binding domains

  • Test these mutants in rescue experiments to determine which domains are essential

  • Particularly focus on the KH3-KH4 domain interface, which has been identified as crucial for binding to certain targets

What are the considerations when using IGF2BP1 antibodies to study developmental processes?

Studying IGF2BP1 in developmental contexts presents unique challenges:

• Temporal expression patterns: IGF2BP1 expression is tightly regulated during development, being primarily restricted to embryonic stages and downregulated after birth . Researchers must:

  • Select appropriate developmental timepoints based on known expression patterns

  • Use sensitive detection methods for low-expression periods

  • Consider conditional knockout models for stage-specific analysis

• Tissue specificity: Different tissues exhibit varying levels of IGF2BP1 expression during development. Key considerations include:

  • Validating antibody performance in specific tissues of interest

  • Using appropriate tissue-specific controls

  • Accounting for potential cross-reactivity with other IGF2BP family members expressed in the same tissues

• Technical approaches:

  • For embryonic studies, whole-mount immunohistochemistry may be preferable to tissue sectioning

  • For early developmental stages, consider in situ hybridization as a complementary approach

  • Use appropriate fixation protocols that preserve both protein epitopes and RNA integrity for dual-labeling experiments

• Phenotypic analysis: When studying IGF2BP1 knockout models, carefully assess:

  • Developmental timing effects, as complete knockout of IGF2BP1 affects postnatal survival

  • Cell-specific phenotypes, such as neuronal morphology and connectivity

  • Compensatory mechanisms by other IGF2BP family members

What are the optimal fixation and antigen retrieval protocols for IGF2BP1 immunohistochemistry?

Optimizing immunohistochemical detection of IGF2BP1 requires careful consideration of fixation and antigen retrieval:

• Fixation recommendations:

  • 10% neutral buffered formalin is generally suitable for most tissues

  • Fixation time should be optimized (typically 24-48 hours for standard tissues)

  • For dual RNA-protein detection, consider methanol-based fixatives that better preserve RNA integrity

• Antigen retrieval protocols:

  • Primary recommendation: Heat-induced epitope retrieval using TE buffer at pH 9.0

  • Alternative method: Citrate buffer at pH 6.0 if the primary method yields suboptimal results

  • For paraffin-embedded tissues, perform retrieval for 15-20 minutes at 95-100°C

• Blocking conditions:

  • Use 5-10% normal serum from the same species as the secondary antibody

  • Consider adding 0.1-0.3% Triton X-100 for improved antibody penetration

  • Block for 1-2 hours at room temperature to minimize background

• Antibody optimization:

  • Start with a dilution range of 1:50-1:500 for primary IGF2BP1 antibody

  • Incubate primary antibody overnight at 4°C for optimal sensitivity

  • Test multiple antibody concentrations to determine optimal signal-to-noise ratio

How should researchers optimize RNA immunoprecipitation (RIP) protocols for IGF2BP1?

RNA immunoprecipitation (RIP) is a crucial technique for identifying RNA targets of IGF2BP1. Optimization considerations include:

• Crosslinking considerations:

  • UV crosslinking (254 nm) is preferred for direct RNA-protein interactions

  • Formaldehyde crosslinking (1% for 10 minutes) can capture larger ribonucleoprotein complexes

  • For IGF2BP1 specifically, both methods have been successfully employed, with UV crosslinking providing more stringent results

• Lysis conditions:

  • Use NP-40 based lysis buffers (typically 0.5-1%) with RNase inhibitors

  • Include protease inhibitors to prevent degradation of IGF2BP1

  • Consider sonication parameters carefully to maintain RNA integrity

• Antibody selection and amount:

  • Choose antibodies validated specifically for RIP applications

  • Use 2-5 μg of antibody per 1 mg of protein lysate

  • Include appropriate isotype control antibodies to assess non-specific binding

• Washing stringency:

  • Perform initial washes with low-stringency buffers

  • Increase stringency in subsequent washes to reduce background

  • Optimize salt concentration (typically 150-300 mM) to maintain specific interactions

• RNA isolation and analysis:

  • Extract RNA using phenol-chloroform or commercial kits designed for small RNA amounts

  • Validate enrichment using RT-qPCR of known targets (e.g., β-actin mRNA)

  • For discovery approaches, proceed to RNA-seq or microarray analysis

What validation strategies are essential when using IGF2BP1 antibodies in knockout/knockdown studies?

When using IGF2BP1 antibodies in knockout/knockdown experiments, rigorous validation is critical:

• Efficiency verification:

  • Confirm knockout/knockdown efficiency at both mRNA level (RT-qPCR) and protein level (Western blot)

  • Quantify the reduction and report as percentage of control expression

  • Verify stability of the knockdown/knockout over experimental timeframe

• Specificity controls:

  • Include proper negative controls (non-targeting siRNA, scrambled shRNA, or wild-type cells)

  • Test for off-target effects on other IGF2BP family members

  • Consider rescue experiments with exogenous IGF2BP1 expression to confirm phenotype specificity

• Antibody validation in knockout context:

  • Confirm complete absence of signal in knockout samples when using the antibody

  • If residual signal is observed, investigate potential cross-reactivity

  • For knockdown models, verify that signal reduction correlates with knockdown efficiency

• Functional assessment:

  • Examine effects on known IGF2BP1 target RNAs (e.g., β-actin)

  • Assess phenotypic changes consistent with IGF2BP1 loss (cell morphology, motility)

  • Evaluate consequences on downstream pathways (e.g., KRAS signaling)

What are the critical parameters for using IGF2BP1 antibodies in co-immunoprecipitation studies?

Co-immunoprecipitation (Co-IP) is valuable for identifying protein interaction partners of IGF2BP1. Critical parameters include:

• Lysis buffer composition:

  • Use non-denaturing buffers to preserve protein-protein interactions

  • Typical composition: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40/Triton X-100

  • Include protease inhibitors and phosphatase inhibitors if studying phosphorylation-dependent interactions

• Pre-clearing strategy:

  • Pre-clear lysates with appropriate beads (Protein A/G) to reduce non-specific binding

  • Use species-matched IgG controls to identify non-specific interactions

  • Optimize pre-clearing time (typically 1-2 hours at 4°C)

• Antibody considerations:

  • Use antibodies validated specifically for immunoprecipitation

  • Determine optimal antibody amount through titration experiments

  • Consider using different antibodies recognizing distinct epitopes to confirm results

• Washing conditions:

  • Balance washing stringency to maintain specific interactions while removing background

  • Perform 4-5 washes with buffers containing 150-300 mM salt

  • Consider including detergents at reduced concentrations (0.1-0.5%) in wash buffers

• Detection strategies:

  • Western blot for known or suspected interaction partners

  • Mass spectrometry for unbiased identification of the interactome

  • Consider RNase treatment controls to distinguish RNA-dependent interactions

How should researchers address discrepancies in IGF2BP1 detection between different antibodies?

When faced with inconsistent results between different IGF2BP1 antibodies, researchers should systematically troubleshoot:

• Epitope mapping comparison:

  • Determine the specific epitopes recognized by each antibody

  • Antibodies targeting different domains may yield different results if:

    • Post-translational modifications mask specific epitopes

    • Alternative splicing produces variants lacking certain domains

    • Protein interactions occlude specific epitopes

• Validation approach:

  • Test antibodies in knockout/knockdown systems to confirm specificity

  • Compare reactivity across multiple applications (WB, IHC, IF)

  • Examine cross-reactivity with other IGF2BP family members

• Technical considerations:

  • Optimize protocols specifically for each antibody (dilution, incubation time, buffer conditions)

  • Consider differences in antibody format (polyclonal vs. monoclonal)

  • Test different antigen retrieval methods for IHC/IF applications

• Resolution strategies:

  • Use multiple antibodies targeting different epitopes in parallel

  • Validate results with complementary techniques (e.g., mass spectrometry)

  • Consider reporter-tagged IGF2BP1 expression as an alternative approach

What factors contribute to variability in IGF2BP1 protein detection by Western blot?

Several factors can affect the consistent detection of IGF2BP1 in Western blot experiments:

• Molecular weight variation:

  • While the calculated molecular weight of IGF2BP1 is 63 kDa, it typically appears at 65-70 kDa on SDS-PAGE

  • This discrepancy may result from:

    • Post-translational modifications (phosphorylation, ubiquitination)

    • Protein conformational effects on migration

    • Splice variants (though the main isoform is predominant)

• Sample preparation issues:

  • Incomplete cell lysis may result in variable extraction efficiency

  • Protein degradation during preparation can produce fragments or reduced signal

  • Phosphatase activity during extraction may alter migration patterns

• Technical variables:

  • Transfer efficiency variations, particularly for larger proteins

  • Blocking reagent compatibility with specific antibodies

  • Exposure time optimization for proper signal detection

• Biological factors:

  • Expression level differences between cell types and tissues

  • Growth conditions affecting post-translational modifications

  • Cell cycle-dependent expression patterns

How can researchers reconcile contradictory findings between IGF2BP1 antibody-based assays and mRNA expression data?

Discrepancies between protein detection and mRNA expression may reflect important biological phenomena:

• Post-transcriptional regulation:

  • IGF2BP1 itself regulates RNA stability and translation, creating potential feedback loops

  • Other RNA-binding proteins may regulate IGF2BP1 mRNA

  • miRNAs targeting IGF2BP1 mRNA may cause translational repression without mRNA degradation

• Protein stability differences:

  • Variations in protein half-life between experimental conditions

  • Proteasomal degradation pathways targeting IGF2BP1

  • Cell-type specific differences in post-translational modifications affecting stability

• Technical considerations:

  • Sensitivity differences between RT-qPCR and antibody-based detection

  • Epitope masking in certain cellular contexts

  • Potential cross-reactivity with other family members

• Experimental approach:

  • Use pulse-chase experiments to assess protein synthesis and degradation rates

  • Employ polysome profiling to assess translational efficiency

  • Consider proteomics approaches to complement antibody-based detection

What challenges exist in interpreting IGF2BP1 localization patterns in immunofluorescence studies?

Interpreting subcellular localization of IGF2BP1 requires careful consideration of several factors:

• Dynamic localization patterns:

  • IGF2BP1 shuttles between different cellular compartments based on cellular state

  • Localization may change in response to stimuli or stress conditions

  • Cell cycle-dependent redistribution may occur

• Technical challenges:

  • Fixation method can significantly impact apparent localization

  • Antibody accessibility to different cellular compartments may vary

  • Background fluorescence can obscure genuine signals in certain compartments

• Biological complexity:

  • IGF2BP1 participates in various ribonucleoprotein complexes with distinct localizations

  • RNA-dependent versus RNA-independent localization patterns

  • Co-localization with specific cellular structures (stress granules, P-bodies, etc.)

• Validation approaches:

  • Use multiple antibodies recognizing different epitopes

  • Complement with fluorescently tagged IGF2BP1 in live-cell imaging

  • Perform subcellular fractionation followed by Western blotting

  • Include appropriate controls (knockout/knockdown cells)